Birch Leaf

Metadata

Approved Indications

Commission E (Germany)

• Approved: Irrigation therapy for:
  • Bacterial and inflammatory diseases of the urinary tract
  • Renal gravel
• Also mentioned for: Rheumatic complaints (adjunctive)

ESCOP

• Approved: Irrigation therapy as adjuvant in treatment of bacterial infections of the urinary tract
• Also: Renal gravel

EMA/HMPC

• Traditional Use: To increase the amount of urine to achieve flushing of the urinary tract as an adjuvant in minor urinary complaints
• Based on traditional use criteria (30+ years safe use including 15+ years in EU)
• Adults and adolescents over 12 years of age

Agreement/Disagreement

• Good agreement among Commission E, ESCOP, and HMPC on irrigation therapy for urinary tract conditions
• All classify as traditional use — no “well-established use” designation
• US: Not recognized in mainstream medicine; very limited awareness even in integrative medicine circles
• Birch leaf is one of the least-known urinary herbs outside German-speaking countries

Conditions Treated

• Irrigation therapy for:
  • Bacterial infections of the lower urinary tract (adjunctive, not primary treatment)
  • Inflammatory conditions of the urinary tract
  • Renal gravel (Nierengruess)
  • Prevention of urinary stones
• Rheumatic complaints (adjunctive irrigation therapy) — secondary indication

Mechanism of Action

Primary Mechanisms

1. Aquaretic / Diuretic Effect

   • Increases urine volume without significant electrolyte loss
   • Flavonoid glycosides believed to mediate diuretic activity
   • Animal studies confirm dose-dependent increase in urine output
   • Mechanism may involve increased renal blood flow and glomerular filtration

2. Anti-inflammatory Activity

   • Flavonoids and triterpene saponins contribute to anti-inflammatory effects
   • In vitro studies demonstrate anti-inflammatory properties
   • May reduce inflammation in urinary tract tissue

3. Antioxidant Activity

   • Phenolic compounds provide significant antioxidant capacity
   • May protect urinary tract tissue from oxidative stress

4. Gastroprotective Effect

   • Animal studies show gastroprotective properties
   • Relevant for tolerability during oral administration

Key Bioactive Compounds

• Flavonoid glycosides (minimum 1.5% expressed as hyperoside):
  • Hyperoside (quercetin-3-O-galactoside): ~0.8% — principal marker compound
  • Avicularin (quercetin-3-O-arabinoside)
  • Quercitrin (quercetin-3-O-rhamnoside)
  • Myricetin glycosides (myricetin-3-O-galactoside)
  • Kaempferol glycosides
  • Quercetin glucuronide (~0.36%)
• Triterpene saponins: Betulin, betulinic acid, lupeol (anti-inflammatory)
• Phenolic acids: Chlorogenic acid (~0.28%), caffeic acid
• Essential oil (minor): Sesquiterpenes
• Vitamin C (minor)
• Tannins: Proanthocyanidins (minor)

European Pharmacopoeia Standard

• Birch leaf: minimum 1.5% flavonoids expressed as hyperoside (C21H20O12)
• Standardization to hyperoside content is the pharmacopoeial standard

Clinical Evidence Summary

Clinical Studies

• Limited: Very few controlled clinical trials specifically on birch leaf monotherapy
• One clinical study showed birch leaf tea can reduce inflammation and irritation of the urinary tract and may help with kidney stone elimination [UNCERTAIN — details of study design unclear]
• Some effectiveness suggested against urinary tract infections in limited studies

Pharmacological Studies

• In vitro: Diuretic, anti-inflammatory, and antioxidant properties confirmed
• In vivo (animal): Diuretic and gastroprotective effects demonstrated
• Animal studies on birch leaf extract (BLE) show dose-dependent diuretic activity

Evidence Base

• The evidence for birch leaf is overwhelmingly traditional and pharmacological rather than clinical-trial-based
• The EMA assessment explicitly notes that “although there is insufficient evidence from clinical trials, the effectiveness of these herbal medicines is plausible”
• This is one of the herbs where European regulatory frameworks (accepting traditional use evidence) and US evidence standards diverge most sharply

Evidence Limitations

• No large RCTs
• No head-to-head comparisons with other diuretic herbs or pharmaceutical diuretics
• Most evidence is from animal models and in vitro studies
• Traditional use documentation is the primary basis for regulatory approval
• [NEEDS-RESEARCH: Controlled clinical trials in humans]

European vs US/Anglophone Consensus

Safety Profile

Contraindications

• Conditions requiring reduced fluid intake: Severe cardiac insufficiency, severe renal failure, edema from cardiac or renal causes (because irrigation therapy requires high fluid intake of 2+ liters/day)
• Known hypersensitivity to birch or related species (potential cross-reactivity with birch pollen allergy — though leaf preparations may or may not trigger this)

Drug Interactions

• Diuretics: Potential additive effect; monitor fluid and electrolyte balance
• Lithium: May alter lithium excretion
• Antihypertensives: Possible additive hypotensive effect
• No significant drug interactions formally documented

Side Effects

• Uncommon: Diarrhea, nausea, vomiting
• Rare: Allergic reactions (itching, rash, stuffy/runny nose) — particularly in individuals with birch pollen allergy
• Overall: Well-tolerated; side effects are infrequent and mild

Pregnancy/Lactation

• Not recommended during pregnancy and lactation (EMA/HMPC)
• Insufficient safety data
• No evidence of specific harm, but standard precautionary avoidance

Age Restrictions

• Not recommended for children under 12 years (EMA/HMPC)

Clinical Dosage

Standardized Dosage Forms

Standardization

• Minimum 1.5% total flavonoids expressed as hyperoside (European Pharmacopoeia)
• Hyperoside content is the primary quality marker

Key Products

• Birkenblatter-Tee (various German manufacturers): Dried birch leaf for tea preparation
• Often included in combination diuretic teas (“Blasen- und Nierentee” / bladder and kidney tea)
• Species diureticae: Traditional European diuretic tea blend containing birch leaf with other herbs (horsetail, goldenrod)
• Combination products are more common than birch leaf monotherapy products

Critical: Fluid Intake Requirement

• Minimum 2 liters/day fluid intake during irrigation therapy
• The diuretic herb + copious fluid = therapeutic flushing effect
• Without adequate hydration, the therapeutic approach is incomplete

Duration of Treatment

• Suitable for medium-term use (weeks to a few months)
• Consult physician if symptoms persist beyond 2 weeks
• No specific maximum duration established, but ongoing medical supervision recommended

Sources

• EMA Assessment Report on Betula pendula/pubescens folium
• EMA Herbal Monograph on Betula pendula/pubescens
• EMA Public Summary — Birch Leaf
• ESCOP Monograph — Betulae folium
• Birch Genus Review — Phytochemistry/Pharmacology (PMC)
• Darwin Nutrition — Birch Benefits/Dosage/Contraindications
• RxList — Birch

Connections

• See Goldenrod and Horsetail for other irrigation therapy herbs